Bio-Rad Laboratories Inc BIO.B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
-
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
-
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
-
Bio-Rad Reports Second-Quarter 2026 Financial Results
-
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
Trading Information
- Previous Close Price
- $365.08
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–365.08
- Bid/Ask
- $264.26 / $469.15
- Shares Outstanding
- 26.74M
- Market Cap
- $9.74B
- Volume/Avg
- 37 / 24
Key Statistics
- Price/Earnings (Normalized)
- 39.34
- Price/Sales
- 3.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.40%
Company Profile
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 7,450
- Website
- https://www.bio-rad.com
Competitors
Valuation
|
Metric
|
BIO.B
|
SRT3
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 39.34 | 75.36 | 27.44 |
Price/Book Value | 1.36 | 6.15 | 2.98 |
Price/Sales | 3.79 | 4.85 | 6.31 |
Price/Cash Flow | 26.48 | 24.58 | 22.11 |
Price/Earnings
BIO.B
SRT3
DHR
Financial Strength
|
Metric
|
BIO.B
|
SRT3
|
DHR
|
|---|---|---|---|
Quick Ratio | 2.14 | 0.48 | 1.03 |
Current Ratio | 3.14 | 1.14 | 1.65 |
Interest Coverage | 6.38 | 3.66 | 16.95 |
Quick Ratio
BIO.B
SRT3
DHR
Profitability
|
Metric
|
BIO.B
|
SRT3
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 2.47% | 3.06% | 5.34% |
Return on Equity (Normalized) | 3.53% | 10.99% | 8.59% |
Return on Invested Capital (Normalized) | 2.66% | 4.84% | 6.45% |
Return on Assets
BIO.B
SRT3
DHR
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|?P#!gx | LOCK|B<S@f | $181B | |||
| Medtronic PLC
MDT
| LOCK|dcyJM#! | LOCK|>pZCY | $121B | |||
| Stryker Corp
SYK
| LOCK|Hjm!xB% | LOCK|<@ | $113B | |||
| Boston Scientific Corp
BSX
| LOCK|%hJsp# | LOCK|^&mVc | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|>sjSX!N | LOCK|NB$> | $50B | |||
| DexCom Inc
DXCM
| LOCK|&<HrkBZ | LOCK|Ky@c@ | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|dFF#JY? | LOCK|?m | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|>yx | LOCK|Wy | $25B | |||
| Steris PLC
STE
| LOCK|!<$BbWL | LOCK|CPym | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|J?&vf?m> | LOCK|%b# | $18B |
United States